A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
References
- Forouzanfar M, Murray CJL, Vos T, Alexander L, Bachman V, Biryukov S, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(10010): 2287–2323. DOI: 10.1016/S0140-6736(15)00128-2
- Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. Journal of the American College of Cardiology. 2017; 70(1): 1–25. DOI: 10.1016/j.jacc.2017.04.052
- Zhu JZ, Manne-Goehler J, Agarwal A, Bahendeka SK, Damasceno A, Marcus ME, et al. Medication use for cardiovascular disease prevention in 40 low- and middle-income countries. Journal of the American College of Cardiology. 2023; 81(6): 620–622. DOI: 10.1016/j.jacc.2022.12.003
- Banerjee A, Khandelwal S, Nambiar L, Saxena M, Peck V, Moniruzzaman M, et al. Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: A systematic review. Open Heart. 2016; 3:
e000438 . DOI: 10.1136/openhrt-2016-000438 - Jagannathan R, Patel SA, Ali MK, Narayan KM. Global updates on cardiovascular disease mortality trends and attribution of traditional risk factors. Current Diabetes Reports. 2019; 19: 44. DOI: 10.1007/s11892-019-1161-2
- World Health Organization.
Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions . Geneva. 2002; 1–3 August. - Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326(7404): 1419. DOI: 10.1136/bmj.326.7404.1419
- Rao S, Siddiqi TJ, Khan MS, Michos ED, Navar AM, Wang TJ, et al. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials. Progress in Cardiovascular Diseases. 2022; 73: 48–55. DOI: 10.1016/j.pcad.2022.01.005
- Joseph P, Roshandel G, Gao P, Pais P, Lonn E, Xavier D, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: An individual participant data meta-analysis. Lancet. 2021; 398(10306): 1133–1146. DOI: 10.1016/S0140-6736(21)01827-4
- Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023; 44(38): 3720–3826. DOI: 10.1093/eurheartj/ehad191
- Wald NJ, Luteij JM, Morris JK, Taylor D, Oppenheimer P. Cost–benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke. European Journal of Epidemiology. 2016; 31: 415–426. DOI: 10.1007/s10654-016-0122-1
- Huffman M, Agarwal A, Zhu JJ, et al. An application to include fixed dose combinations in the WHO Model List of Essential Medicines for primary and secondary prevention of atherosclerotic cardiovascular diseases in adults; 2023. Available from:
https://cdn.who.int/media/docs/default-source/essential-medicines/2023-eml-expert-committee/applications-for-addition-of-new-medicines/a16_cvd-fdc.pdf?sfvrsn=a9d4588_2 . - Murphy A, Willis R, Ansbro E, Masri S, Kabbara N, Dabbousy T, et al. Implementation of fixed-dose combination therapy for secondary prevention of atherosclerotic cardiovascular disease among Syrian refugees in Lebanon: a qualitative evaluation. BMC Health Services Research. 2022; 22(1): 744. DOI: 10.1186/s12913-022-08040-z
- WHO/HAI.
Measuring medicine prices, availability, affordability and price components. 2nd ed . Geneva, Switzerland: WHO; 2008. - van Mourik MS, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovascular Disorders. 2010; 10: 25. DOI: 10.1186/1471-2261-10-25
- Webster R, Castellano JM, Onuma OK. Putting polypills into practice: Challenges and lessons learned. Lancet. 2017; 389(10073): 1066–1074. DOI: 10.1016/S0140-6736(17)30558-5
- Webster R, Rodgers A. Polypill: Progress and challenges to global use—Update on the trials and policy implementation. Current Cardiology Reports. 2015; 17(12): 121. DOI: 10.1007/s11886-015-0673-x
- Webster R, Murphy A, Bygrave H, Ansbro É, Grobbee DE, Perel P. Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases. Global Heart. 2020 Aug 19; 15(1): 57. DOI: 10.5334/gh.860
- Peacocke EF, Myhre SL, Foss HS, Gopinathan U. National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis. PLoS Medicine. 2022; 19(3):
e1003944 . DOI: 10.1371/journal.pmed.1003944 - Satheesh G, Dhurjati R, Huffman MD, et al. Standardized treatment protocols for hypertension: global availability, characteristics, and alignment with the hypertension guideline recommendations. Journal of Hypertension. 2024; 42(5): 902–908. DOI: 10.1097/HJH.0000000000003636
- Salam A, Huffman MD, Kanukula R, Prasad EH, Sharma A, Heller DJ, et al. Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost. Journal of Clinical Hypertension (Greenwich). 2020; 22(10): 1769–1779. DOI: 10.1111/jch.14009
- Salam A, Praveen D, Patel A, Tewari A, Webster R. Barriers and facilitators to the use of cardiovascular fixed-dose combination medication (Polypills) in Andhra Pradesh, India: A mixed-methods study. Global Heart. 2019; 14(3): 303–310. DOI: 10.1016/j.gheart.2019.07.002
- May CR, Albers B, Bracher M, Finch TL, Gilbert A, Girling M, et al. Translational framework for implementation evaluation and research: A normalisation process theory coding manual for qualitative research and instrument development. Implementation Science. 2022; 17(1): 19. DOI: 10.1186/s13012-022-01191-x
DOI: https://doi.org/10.5334/gh.1335 | Journal eISSN: 2211-8179
Language: English
Submitted on: Dec 16, 2023
Accepted on: Jun 10, 2024
Published on: Jul 1, 2024
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2024 Gautam Satheesh, Bishal Gyawali, Marie France Chan Sun, Mark D. Huffman, Amitava Banerjee, Pablo Perel, Adrianna Murphy, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.